tiprankstipranks
Sutro Biopharma Inc (DE:S090)
FRANKFURT:S090
Germany Market
S090
Sutro Biopharma
RESEARCH TOOLSreports

Sutro Biopharma (S090) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

S090 Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
0 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Sutro
Biopharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

S090 Stock 12 Month Forecast

Average Price Target

€43.80
▲(112.63% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Sutro Biopharma in the last 3 months. The average price target is €43.80 with a high forecast of €47.94 and a low forecast of €41.09. The average price target represents a 112.63% change from the last price of €20.60.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","48":"€48","15.75":"€15.75","26.5":"€26.5","37.25":"€37.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.93933592,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€47.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.801714665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€43.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.09085936,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€41.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,15.75,26.5,37.25,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.2,23.256871993846154,25.313743987692305,27.37061598153846,29.427487975384615,31.48435996923077,33.541231963076925,35.598103956923076,37.65497595076923,39.711847944615386,41.768719938461544,43.82559193230769,45.88246392615385,{"y":47.93933592,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.2,22.93859343576923,24.67718687153846,26.415780307307692,28.154373743076924,29.892967178846153,31.631560614615385,33.37015405038461,35.108747486153845,36.84734092192308,38.58593435769231,40.32452779346154,42.063121229230774,{"y":43.801714665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.2,22.730066104615386,24.26013220923077,25.790198313846155,27.32026441846154,28.850330523076924,30.38039662769231,31.910462732307693,33.44052883692308,34.970594941538465,36.50066104615385,38.03072715076924,39.560793255384624,{"y":41.09085936,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.189,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€47.94Average Price Target€43.80Lowest Price Target€41.09
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on DE:S090
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
€41.09
Buy
99.47%
Upside
Reiterated
08/17/26
Stifel Nicolaus Sticks to Their Buy Rating for Sutro Biopharma (STRO)
Bank of America Securities Analyst forecast on DE:S090
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
08/14/26
Analysts Conflicted on These Healthcare Names: Definium Therapeutics (NASDAQ: DFTX), Ionis Pharmaceuticals (NASDAQ: IONS) and Sutro Biopharma (NASDAQ: STRO)
H.C. Wainwright Analyst forecast on DE:S090
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
€42.8
Buy
107.78%
Upside
Reiterated
08/13/26
Maldonado Reiterates Buy on Sutro, Sees STRO-004 Data as Proof-of-Concept and Keeps $50 Price Target Unchanged
Wells Fargo Analyst forecast on DE:S090
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
€41.95
Buy
103.63%
Upside
Assigned
08/13/26
Sutro Biopharma (STRO) Gets a Buy from Wells Fargo
Barclays Analyst forecast on DE:S090
Lukas Shumway
Barclays
Barclays
€47.94
Buy
132.72%
Upside
Reiterated
08/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (NASDAQ: STRO), Summit Therapeutics (NASDAQ: SMMT) and Altimmune (NASDAQ: ALT)
Truist Financial Analyst forecast on DE:S090
Supawat Thongthip
Truist Financial
Truist Financial
€42.8
Buy
107.78%
Upside
Reiterated
08/13/26
Truist Financial Keeps Their Buy Rating on Sutro Biopharma (STRO)
LifeSci Capital Analyst forecast on DE:S090
Charles Zhu
LifeSci Capital
LifeSci Capital
€46.23
Buy
124.40%
Upside
Reiterated
08/12/26
Sutro Biopharma: Encouraging STRO-004 Early Data and Solid Execution Support Unchanged $54 Price Target and Buy Rating
TD Cowen Analyst forecast on DE:S090
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/12/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: AgomAb Therapeutics NV ADR (NASDAQ: AGMB), EDAP TMS (NASDAQ: FOCL) and Sutro Biopharma (NASDAQ: STRO)
Wedbush Analyst forecast on DE:S090
David Nierengarten
Wedbush
Wedbush
€51.36
Buy
149.34%
Upside
Upgraded
05/18/26
Sutro Biopharma upgraded to Outperform from Neutral at WedbushSutro Biopharma upgraded to Outperform from Neutral at Wedbush
Leerink Partners Analyst forecast on DE:S090
Andrew Berens
Leerink Partners
Leerink Partners
€32.53→€36.81
Buy
78.69%
Upside
Assigned
05/15/26
Sutro Biopharma price target raised to $43 from $38 at LeerinkSutro Biopharma price target raised to $43 from $38 at Leerink
Mizuho Securities Analyst forecast on DE:S090
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
€42.8
Buy
107.78%
Upside
Initiated
04/30/26
Sutro Biopharma initiated with an Outperform at MizuhoSutro Biopharma initiated with an Outperform at Mizuho
Citizens JMP Analyst forecast on DE:S090
Reni Benjamin
Citizens JMP
Citizens JMP
€29.96→€35.1
Buy
70.38%
Upside
Reiterated
04/23/26
Sutro Biopharma price target raised to $41 from $35 at CitizensSutro Biopharma price target raised to $41 from $35 at Citizens
Deutsche Bank Analyst forecast on DE:S090
James Shin
Deutsche Bank
Deutsche Bank
€43.66→€47.08
Buy
128.56%
Upside
Reiterated
03/25/26
Sutro Biopharma price target raised to $55 from $51 at Deutsche BankSutro Biopharma price target raised to $55 from $51 at Deutsche Bank
Piper Sandler Analyst forecast on DE:S090
Edward Tenthoff
Piper Sandler
Piper Sandler
€17.12
Buy
-16.89%
Downside
Reiterated
12/04/25
Sutro Biopharma (STRO) Receives a Buy from Piper Sandler
Jefferies Analyst forecast on DE:S090
Roger Song
Jefferies
Jefferies
€59.92→€34.24
Buy
66.23%
Upside
Reiterated
09/09/25
Sutro Biopharma price target lowered to $4 from $7 at JefferiesSutro Biopharma price target lowered to $4 from $7 at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on DE:S090
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
€41.09
Buy
99.47%
Upside
Reiterated
08/17/26
Stifel Nicolaus Sticks to Their Buy Rating for Sutro Biopharma (STRO)
Bank of America Securities Analyst forecast on DE:S090
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
08/14/26
Analysts Conflicted on These Healthcare Names: Definium Therapeutics (NASDAQ: DFTX), Ionis Pharmaceuticals (NASDAQ: IONS) and Sutro Biopharma (NASDAQ: STRO)
H.C. Wainwright Analyst forecast on DE:S090
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
€42.8
Buy
107.78%
Upside
Reiterated
08/13/26
Maldonado Reiterates Buy on Sutro, Sees STRO-004 Data as Proof-of-Concept and Keeps $50 Price Target Unchanged
Wells Fargo Analyst forecast on DE:S090
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
€41.95
Buy
103.63%
Upside
Assigned
08/13/26
Sutro Biopharma (STRO) Gets a Buy from Wells Fargo
Barclays Analyst forecast on DE:S090
Lukas Shumway
Barclays
Barclays
€47.94
Buy
132.72%
Upside
Reiterated
08/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (NASDAQ: STRO), Summit Therapeutics (NASDAQ: SMMT) and Altimmune (NASDAQ: ALT)
Truist Financial Analyst forecast on DE:S090
Supawat Thongthip
Truist Financial
Truist Financial
€42.8
Buy
107.78%
Upside
Reiterated
08/13/26
Truist Financial Keeps Their Buy Rating on Sutro Biopharma (STRO)
LifeSci Capital Analyst forecast on DE:S090
Charles Zhu
LifeSci Capital
LifeSci Capital
€46.23
Buy
124.40%
Upside
Reiterated
08/12/26
Sutro Biopharma: Encouraging STRO-004 Early Data and Solid Execution Support Unchanged $54 Price Target and Buy Rating
TD Cowen Analyst forecast on DE:S090
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/12/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: AgomAb Therapeutics NV ADR (NASDAQ: AGMB), EDAP TMS (NASDAQ: FOCL) and Sutro Biopharma (NASDAQ: STRO)
Wedbush Analyst forecast on DE:S090
David Nierengarten
Wedbush
Wedbush
€51.36
Buy
149.34%
Upside
Upgraded
05/18/26
Sutro Biopharma upgraded to Outperform from Neutral at WedbushSutro Biopharma upgraded to Outperform from Neutral at Wedbush
Leerink Partners Analyst forecast on DE:S090
Andrew Berens
Leerink Partners
Leerink Partners
€32.53→€36.81
Buy
78.69%
Upside
Assigned
05/15/26
Sutro Biopharma price target raised to $43 from $38 at LeerinkSutro Biopharma price target raised to $43 from $38 at Leerink
Mizuho Securities Analyst forecast on DE:S090
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
€42.8
Buy
107.78%
Upside
Initiated
04/30/26
Sutro Biopharma initiated with an Outperform at MizuhoSutro Biopharma initiated with an Outperform at Mizuho
Citizens JMP Analyst forecast on DE:S090
Reni Benjamin
Citizens JMP
Citizens JMP
€29.96→€35.1
Buy
70.38%
Upside
Reiterated
04/23/26
Sutro Biopharma price target raised to $41 from $35 at CitizensSutro Biopharma price target raised to $41 from $35 at Citizens
Deutsche Bank Analyst forecast on DE:S090
James Shin
Deutsche Bank
Deutsche Bank
€43.66→€47.08
Buy
128.56%
Upside
Reiterated
03/25/26
Sutro Biopharma price target raised to $55 from $51 at Deutsche BankSutro Biopharma price target raised to $55 from $51 at Deutsche Bank
Piper Sandler Analyst forecast on DE:S090
Edward Tenthoff
Piper Sandler
Piper Sandler
€17.12
Buy
-16.89%
Downside
Reiterated
12/04/25
Sutro Biopharma (STRO) Receives a Buy from Piper Sandler
Jefferies Analyst forecast on DE:S090
Roger Song
Jefferies
Jefferies
€59.92→€34.24
Buy
66.23%
Upside
Reiterated
09/09/25
Sutro Biopharma price target lowered to $4 from $7 at JefferiesSutro Biopharma price target lowered to $4 from $7 at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sutro Biopharma

3 Months
Reni BenjaminCitizens JMP
Success Rate
14/36 ratings generated profit
39%
Average Return
-8.58%
Copying Reni Benjamin's trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of -8.58% per trade.
1 Year
Edward TenthoffPiper Sandler
Success Rate
6/17 ratings generated profit
35%
Average Return
+3.52%
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of +3.52% per trade.
2 Years
Tara BancroftTD Cowen
Success Rate
4/13 ratings generated profit
31%
Average Return
+19.74%
Copying Tara Bancroft's trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of +19.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

S090 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
7
8
8
9
Buy
8
12
9
5
2
Hold
1
1
0
0
0
Sell
0
1
1
1
1
Strong Sell
0
0
0
0
0
total
10
21
18
14
12
In the current month, S090 has received 11 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. S090 average Analyst price target in the past 3 months is 43.80.
Each month's total comprises the sum of three months' worth of ratings.

S090 Financial Forecast

S090 Earnings Forecast

Next quarter’s earnings estimate for S090 is -€1.44 with a range of -€2.47 to €0.66. The previous quarter’s EPS was -€2.01. S090 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year S090 has Performed in-line its overall industry.
Next quarter’s earnings estimate for S090 is -€1.44 with a range of -€2.47 to €0.66. The previous quarter’s EPS was -€2.01. S090 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year S090 has Performed in-line its overall industry.

S090 Sales Forecast

Next quarter’s sales forecast for S090 is €11.75M with a range of €2.16M to €43.16M. The previous quarter’s sales results were €8.49M. S090 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year S090 has Performed in-line its overall industry.
Next quarter’s sales forecast for S090 is €11.75M with a range of €2.16M to €43.16M. The previous quarter’s sales results were €8.49M. S090 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year S090 has Performed in-line its overall industry.

S090 Stock Forecast FAQ

What is DE:S090’s average 12-month price target, according to analysts?
Based on analyst ratings, Sutro Biopharma Inc’s 12-month average price target is 43.80.
    What is DE:S090’s upside potential, based on the analysts’ average price target?
    Sutro Biopharma Inc has 112.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sutro Biopharma Inc a Buy, Sell or Hold?
          Sutro Biopharma Inc has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Sutro Biopharma Inc’s share price target?
            The average share price target for Sutro Biopharma Inc is 43.80. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €47.94 ,and the lowest forecast is €41.09. The average share price target represents 112.63% Increase from the current price of €20.6.
              What do analysts say about Sutro Biopharma Inc?
              Sutro Biopharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Sutro Biopharma Inc?
                To buy shares of DE:S090, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.